UY36197A - BIOLOGICAL CHARACTERIZATION OF A PHARMACOLOGICAL PRODUCT DERIVED FROM GLATIRAMER ACETATE BY HUMAN AND NON-HUMAN MAMMAL CELLS - Google Patents
BIOLOGICAL CHARACTERIZATION OF A PHARMACOLOGICAL PRODUCT DERIVED FROM GLATIRAMER ACETATE BY HUMAN AND NON-HUMAN MAMMAL CELLSInfo
- Publication number
- UY36197A UY36197A UY0001036197A UY36197A UY36197A UY 36197 A UY36197 A UY 36197A UY 0001036197 A UY0001036197 A UY 0001036197A UY 36197 A UY36197 A UY 36197A UY 36197 A UY36197 A UY 36197A
- Authority
- UY
- Uruguay
- Prior art keywords
- human
- glatiramer acetate
- product derived
- mammal cells
- biological characterization
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La presente invención provee un proceso de caracterización de una sustancia o producto farmacológico relacionado con acetato de glatiramer que comprende los pasos de: a) obtener un lote de la sustancia o producto farmacológico relacionado con acetato de glatiramer; b) poner en contacto células de mamífero con una cantidad de la sustancia o producto farmacológico relacionado con acetato de glatiramer del paso a); y c) determinar el nivel de expresión de al menos uno de los genes descritos en este documento, caracterizando así la sustancia o producto farmacológico relacionado con acetato de glatiramer del paso a).The present invention provides a process for characterizing a substance or drug product related to glatiramer acetate comprising the steps of: a) obtaining a batch of the drug substance or product related to glatiramer acetate; b) contacting mammalian cells with an amount of the substance or drug product related to glatiramer acetate from step a); and c) determining the level of expression of at least one of the genes described herein, thus characterizing the drug substance or product related to glatiramer acetate from step a).
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462019857P | 2014-07-01 | 2014-07-01 | |
US201462020358P | 2014-07-02 | 2014-07-02 | |
US201462025953P | 2014-07-17 | 2014-07-17 | |
US201462047437P | 2014-09-08 | 2014-09-08 | |
US201462078369P | 2014-11-11 | 2014-11-11 | |
US201562134245P | 2015-03-17 | 2015-03-17 | |
US201562162308P | 2015-05-15 | 2015-05-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY36197A true UY36197A (en) | 2016-01-29 |
Family
ID=55020098
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001036197A UY36197A (en) | 2014-07-01 | 2015-06-29 | BIOLOGICAL CHARACTERIZATION OF A PHARMACOLOGICAL PRODUCT DERIVED FROM GLATIRAMER ACETATE BY HUMAN AND NON-HUMAN MAMMAL CELLS |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP3164710A4 (en) |
CA (1) | CA2952849A1 (en) |
IL (1) | IL249686A0 (en) |
TW (1) | TW201610169A (en) |
UY (1) | UY36197A (en) |
WO (1) | WO2016004250A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018053109A1 (en) * | 2016-09-14 | 2018-03-22 | Teva Pharmaceutical Industries Ltd. | Gene expression characterization of a glatiramer acetate related drug product in mammalian and human cells |
CN116637123B (en) * | 2023-06-07 | 2024-02-13 | 上海市东方医院(同济大学附属东方医院) | Application of reagent for knocking down or down expression of C15orf39 gene in preparation of medicines for treating gastric cancer |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010530975A (en) * | 2007-06-21 | 2010-09-16 | モメンタ ファーマシューティカルズ インコーポレイテッド | Copolymer assay |
-
2015
- 2015-06-24 TW TW104120408A patent/TW201610169A/en unknown
- 2015-06-29 UY UY0001036197A patent/UY36197A/en not_active Application Discontinuation
- 2015-07-01 CA CA2952849A patent/CA2952849A1/en not_active Abandoned
- 2015-07-01 WO PCT/US2015/038901 patent/WO2016004250A2/en active Application Filing
- 2015-07-01 EP EP15814349.5A patent/EP3164710A4/en not_active Withdrawn
-
2016
- 2016-12-21 IL IL249686A patent/IL249686A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2016004250A3 (en) | 2016-03-17 |
EP3164710A4 (en) | 2018-04-11 |
TW201610169A (en) | 2016-03-16 |
CA2952849A1 (en) | 2016-01-07 |
EP3164710A2 (en) | 2017-05-10 |
IL249686A0 (en) | 2017-02-28 |
WO2016004250A2 (en) | 2016-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20151980A1 (en) | CHARACTERIZATION OF A GLATIRAMER ACETATE RELATED MEDICINAL PRODUCT | |
EA201890013A1 (en) | METHODS FOR OBTAINING TCR GAMMA DELTAT-CELLS | |
CO2017000507A2 (en) | Chimeric bcma antigen receptor | |
MX2021008142A (en) | Methods for harvesting mammalian cell cultures. | |
WO2016040862A3 (en) | Integration of auxiliary sensors with point cloud-based haptic rendering and virtual fixtures | |
BR112014000965B8 (en) | METHOD, APPLIANCE AND NON-TRAINER STORAGE MEDIA | |
BR112017007965A2 (en) | computer-implemented method for inferring the activity of a tgf-b cell signaling pathway in an individual; apparatus for inferring the activity of a tgf-b cellular signaling pathway in an individual; non-transient storage medium; computer program; kits for measuring expression levels of three or more tgf-b cell signaling pathway target genes in a sample from an individual; infer the activity of a tgf-b cell signaling pathway in an individual; infer the activity of a tgf-b cell signaling pathway in an individual; and use of the kit | |
EA202092987A3 (en) | LIPID CONTAINING DOCOSAPENTAENIC ACID | |
AR090973A1 (en) | USEFUL ANTIBODIES FOR CANCER DIAGNOSIS | |
CY1122612T1 (en) | METHOD | |
CO2017006156A2 (en) | A method to manufacture a protein of interest, where said protein is expressed in a host cell | |
BR112016024494A2 (en) | peptide analogs with branched amino acid probe (s) | |
UY36870A (en) | NEW INSULIN ANALOGS | |
CO2017005773A2 (en) | Compositions, devices, and ibs sensitivity test methods | |
EA201791275A1 (en) | METHODS OF OBTAINING CTP-MODIFIED POLYPEPTIDES OF LONG-TERM | |
BR112016024895A2 (en) | secretory protein factor with high secretory efficacy and an expression vector comprising the same | |
CL2016002632A1 (en) | Arm calibration system | |
MX2017001979A (en) | In vitro method and apparatus for analysing the behaviour of substances in simulated physiological environment. | |
MX2022003399A (en) | Cellular-based method for determining the potency of defibrotide. | |
MX2017014247A (en) | Methods for assesing the purity of a mesenchymal stem cells preparation. | |
BR112018000168A2 (en) | A manufacturing method of a quality iPS cell | |
UY36197A (en) | BIOLOGICAL CHARACTERIZATION OF A PHARMACOLOGICAL PRODUCT DERIVED FROM GLATIRAMER ACETATE BY HUMAN AND NON-HUMAN MAMMAL CELLS | |
WO2015121636A3 (en) | Fuel source, fuel cell system and associated method | |
WO2015068075A3 (en) | Detection of tau | |
AR101088A1 (en) | BIOLOGICAL CHARACTERIZATION OF A PHARMACOLOGICAL PRODUCT DERIVED FROM GLATIRAMER ACETATE BY HUMAN AND NON-HUMAN MAMMAL CELLS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20220629 |